871353-25-2

Usage

Uses

Used in Pharmaceutical Research:
3-Bromo-2-fluorobenzamide is used as a key intermediate in the synthesis of various pharmaceutical compounds for drug discovery and development. Its unique structure allows it to interact with biological systems, making it a valuable component in creating new medications.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Bromo-2-fluorobenzamide is utilized as a starting material for the creation of more complex organic molecules. Its presence in these reactions can lead to the development of novel chemical entities with potential applications in various industries.
Used in Specialty Chemicals and Materials Production:
3-Bromo-2-fluorobenzamide may also find use in the production of specialty chemicals and materials. Its unique properties can contribute to the development of advanced materials with specific characteristics required for specialized applications.
It is crucial to handle 3-Bromo-2-fluorobenzamide with care due to its potential health and environmental risks if mismanaged. Proper safety measures should be taken to mitigate any risks associated with its use.

InChI:InChI=1/C7H5BrFNO/c8-5-3-1-2-4(6(5)9)7(10)11/h1-3H,(H2,10,11)

Upstream product

• 374554-41-3 3-bromo-2-fluorobenzoyl chloride 
• 1072-85-1 o-fluorobromobenzene 
• 161957-56-8 3-bromo-2-fluorobenzoic acid 

Downstream Products

• 840481-82-5 3-bromo-2-fluoro-benzonitrile 
• 1177558-58-5 1,1-dimethylethyl [(3-bromo-2-fluorophenyl)methyl]carbamate 
• 261723-28-8 (3-bromo-2-fluorophenyl)methanamine 

Relevant academic research and scientific papers

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES

The application relates to compounds of Formula (I'): which modulate the activity of a kinase (e.g., STK4), a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease or disorder associated with the modulation of a kinase, such as STK4.

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.

INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE

The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. A compound represented by the formula (I): wherein R1, R2, R3, R4 are as defined herein; or a salt thereof.

NEW DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION

The present invention relates to compounds which have therapeutic effects against disorders in the central nervous system, and in particular new 4-(ortho, meta-disubstituted phenyl)-1-alkypiperidines and piperazines. (I) wherein R1, R2, R3 and Y are as de